SAHA (suberoylanilide hydroxamic acid, Vorinostat, Zolinza™) is a histone deacetylase (HDAC) inhibitor that binds directly to the catalytic site of the enzyme thereby blocking substrate access. It inhibits class I and class II HDACs at around 50 nM and arrests cell growth in a wide variety of transformed cells in culture at 2.5-5.0 µM.1 SAHA is currently in advanced clinical trials for the treatment of cancer.
1
Marks, P.A., and Breslow, R. Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotech25(1)84-90(2007).
Synonyms
Vorinostat
Suberoylanilide Hydroxamic Acid
Zolinza™
Formal Name
N1-hydroxy-N8-phenyl-octanediamide
CAS Number
149647-78-9
Molecular Formula
C14H20N2O3
Formula Weight
264.3
Formulation
A crystalline solid
Purity
>98%
λmax
243 nm
Stability
2 years
Storage
-20°C
Shipping
Room temperature
in continental US; may vary elsewhere
SMILES
Copy SMILES to clipboard
ONC(=O)CCCCCCC(=O)Nc1ccccc1
Background Reading
Marks, P.A., and Breslow, R. Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotech25(1)84-90(2007).
SAHA is available in the following screening
libraries: